Can a Two-Drug combo stop nerve tumors from turning cancerous?

NCT ID NCT06735820

Recruiting now Disease control Sponsor: AeRang Kim Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial is testing whether combining two drugs—selumetinib and APG-115—can help people with neurofibromatosis type 1 (NF1) who have nerve sheath tumors that are either pre-cancerous or already cancerous. The study aims to find a safe dose and see if the combination can shrink tumors or slow their growth. Participants include adults and some adolescents with measurable tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of two drugs: selumetinib (a MEK inhibitor) and APG-115 (an MDM2 inhibitor)
What this could lead to: If successful, this combination could offer a new treatment option for people with NF1 who have nerve sheath tumors, potentially shrinking tumors or preventing them from turning cancerous.
What could go wrong: This is an early-phase trial, so the combination may not work as hoped or could cause unexpected side effects. The small number of participants (45) also limits how broadly the results can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL NEUROFIBROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical neurofibroma malignant peripheral nerve sheath tumor neurofibromatosis type 1 neurofibrosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL NEUROFIBROMA MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) NEUROFIBROMATOSIS 1 (NF1)

Contacts and locations

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.